Mon, May 16, 2011
Sun, May 15, 2011
[ Sun, May 15th 2011 ] - Market Wire
Teva to Acquire Taiyo
Fri, May 13, 2011
Thu, May 12, 2011
Wed, May 11, 2011
Tue, May 10, 2011
Mon, May 9, 2011
Sun, May 8, 2011
Sat, May 7, 2011
Fri, May 6, 2011
Thu, May 5, 2011
Wed, May 4, 2011
Tue, May 3, 2011
Mon, May 2, 2011
Fri, April 29, 2011
Thu, April 28, 2011
Wed, April 27, 2011
Tue, April 26, 2011
Mon, April 25, 2011
Fri, April 22, 2011
Thu, April 21, 2011
Wed, April 20, 2011
Tue, April 19, 2011
Mon, April 18, 2011

Anacor Pharmaceuticals Announces First Quarter 2011 Financial Results Conference Call and Webcast


//health-fitness.news-articles.net/content/2011/ .. nancial-results-conference-call-and-webcast.html
Published in Health and Fitness on Thursday, April 28th 2011 at 14:11 GMT by Market Wire   Print publication without navigation


PALO ALTO, Calif.--([ BUSINESS WIRE ])--Anacor Pharmaceuticals (NASDAQ:ANAC) will release its financial results for the first quarter ended March 31, 2011, on Thursday May 5, 2011 at approximately 7:00 a.m. ET / 4:00 a.m. PT. The announcement will be followed by a conference call at 8:00 a.m. ET / 5:00 a.m. PT during which management will discuss the companya™s financial results and recent developments. The call can be accessed by dialing (877) 291-1367 (domestic) and (914) 495-8534 (international) five minutes prior to the start of the call and providing the conference ID 63098653. The call will also be webcast live and can be accessed on the Events and Presentations page, under Investors, on the companya™s website at [ www.anacor.com ] and will be available for three months following the call.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered five clinical compounds which are currently in development, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis and atopic dermatitis; and GSK 2251052, or GSK a052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies' research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. For more information visit [ http://www.anacor.com ].


Publication Contributing Sources